The Truth About GLP-1s

How These Medications Work

Glucagon-like peptide-1 (GLP-1) is a natural incretin hormone, a type of gut hormone released after eating that helps regulate blood sugar and appetite. Semaglutide is a selective GLP-1 receptor agonist, approved for both type 2 diabetes and weight management, meaning it mimics this hormone and produces several coordinated effects.1

Tirzepatide, approved for type 2 diabetes, weight management, and certain cases of obstructive sleep apnea, is a dual agonist. It activates both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors. The added GIP activity appears to enhance insulin sensitivity, further supporting weight loss, and may also improve gastrointestinal tolerability relative to pure GLP-1 agonists at comparable efficacy levels.

Both are long-acting peptides given as once-weekly subcutaneous injections, and oral formulations are now available as well. The beneficial effects build gradually as the dose is escalated over several weeks.

What Does the Research Actually Show?

It's worth moving past the trends and looking directly at the trial data.2 Clinical trials (the STEP program for semaglutide; SURMOUNT program for tirzepatide) show substantial, sustained weight loss with these agents, especially when combined with lifestyle modifications.3 In the STEP 1 trial, semaglutide 2.4 mg weekly produced an average weight reduction of roughly 15% over 68 weeks in adults with obesity who did not have diabetes.4 In adults with obesity and type 2 diabetes, the STEP 2 trial found that semaglutide meaningfully improved glycemic control alongside weight loss.5 Head-to-head data generally favor tirzepatide for greater average weight loss.

Weight loss is accompanied by improvements in blood pressure, lipids, and reduced markers of inflammation. For patients with diabetes, these medications also improve glycemic control, often reflected in A1c reductions of 1.5–2% or more. A1c (also called hemoglobin A1c) is a simple blood test that estimates your average blood sugar over the past two to three months, making it one of the main numbers doctors use to track diabetes management over time. In the SELECT trial, semaglutide reduced major adverse cardiovascular events (MACE), a composite of cardiovascular death, heart attack, and stroke, by 20% in adults with cardiovascular disease and overweight or obesity who did not have diabetes.6

Metabolic and Hormonal Effects

Beyond the scale, these medications are associated with a reduction in visceral (abdominal) fat, which drives many metabolic complications and low-grade inflammation. Much of the hormone-specific research in this area has focused on men, where excess adipose tissue converts testosterone to estrogen through a process called aromatization. Losing fat mass, improving insulin sensitivity, and reducing inflammation can raise total and free testosterone in men with obesity-related (functional) hypogonadism, and some data also suggest possible benefits for semen parameters and erectile function in this group, though more research is needed. Some observational cohorts also report lower rates of new erectile dysfunction diagnoses, likely mediated by weight loss, better vascular function, and hormonal improvements.

These agents are not a substitute for directly addressing a hormone deficiency when one is present, nor do they replace resistance training and adequate protein intake to help preserve lean mass during weight loss.

Side Effects and Safety Considerations

The most common side effects are gastrointestinal and usually appear or intensify during dose increases, then improve for most patients. Rates in major trials are substantial, nausea is often reported by 30–45% of patients at higher doses of semaglutide, with somewhat lower or comparable rates for tirzepatide in some comparisons, but symptoms are typically mild to moderate and transient. Practical strategies that help include slower titration when needed, smaller meals, reduced fat content, staying well hydrated, and avoiding lying down soon after eating.

Hypoglycemia risk is low when these medications are used alone but rises if combined with insulin or sulfonylureas, so dose adjustments of those agents are often needed.

Standard Dosing and Titration

Slow, stepwise dose escalation is essential to improve tolerability. The schedules below reflect current labeled guidance for adults; individual plans are always tailored by the prescribing clinician based on response, side effects, and indication (diabetes vs. weight management).

Semaglutide: Weight-Management Dosing

Once-weekly subcutaneous injection, weight-management dosing:7

For the type 2 diabetes indication, escalation typically reaches a maintenance dose of 0.5 mg, 1 mg, or 2 mg. Dose increases occur no sooner than every 4 weeks; delays are appropriate if gastrointestinal symptoms are bothersome.

Tirzepatide: Weight-Management Dosing

Once-weekly subcutaneous injection:

Maintenance doses for weight management are typically 5 mg, 10 mg, or 15 mg, chosen according to efficacy and tolerability. Increases occur in 2.5 mg increments after at least 4 weeks on the current dose.

Injections can be given in the abdomen, thigh, or upper arm at any time of day, with or without food. If a dose is missed, general guidance is to administer the next injection within a few days of the missed date if remembered, then resume the regular weekly schedule.

Putting It Into Practice

These medications are most effective as part of a comprehensive plan that includes nutrition (emphasizing protein and nutrient density), resistance training to protect against muscle loss, cardiovascular activity, sleep, and stress management. Regular follow-up allows monitoring of weight, body composition, metabolic labs, side effects, and, when relevant, hormone levels or sexual health concerns.

When to Talk to a Provider

Anyone considering these agents should discuss their personal medical history, goals, fertility plans, and any concurrent therapies, including hormone therapy, with their clinician. These medications require ongoing coordination, not a one-time prescription.

A good starting point is an honest conversation about your health history, what you're hoping to achieve, and what a realistic, monitored plan looks like.

This article is intended for general educational purposes and does not constitute medical advice. Please consult a qualified healthcare provider for evaluation and treatment recommendations tailored to your individual situation.